Fennec Pharmaceuticals (FENC) Share-based Compensation (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Share-based Compensation data on file, last reported at $6.9 million in Q4 2025.

• Quarterly Share-based Compensation rose 282.72% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 3896.02% YoY) and the FY2025 annual result came in at $7.0 million, up 40.1% from the prior year.
• Share-based Compensation grew to $6.9 million in Q4 2025, from $50000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.9 million in Q4 2025 to a low of -$3.8 million in Q4 2024.
• A 5-year average of $667210.5 and a median of $798000.0 in 2025 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation soared 7165.71% — and 2024, when it tumbled 538.86%.
• Tracing FENC's Share-based Compensation over 5 years: stood at -$2.6 million in 2021, then jumped by 98.71% to -$33000.0 in 2022, then jumped by 2696.97% to $857000.0 in 2023, then plunged by 538.86% to -$3.8 million in 2024, then jumped by 282.72% to $6.9 million in 2025.
• The last three Share-based Compensation figures came in at $6.9 million (Q4 2025), $50000.0 (Q3 2025), and -$687000.0 (Q2 2025), per Business Quant data.